Hongo-Hirasaki Tomoko, Fukutomi Hiroki
Scientific Affairs Group, Bioprocess Division, Asahi Kasei Medical Co., Ltd., Nobeoka, Miyazaki 882-0031, Japan.
Scientific Affairs Group, Bioprocess Division, Asahi Kasei Medical Co., Ltd., Chiyoda-ku, Tokyo 100-0006, Japan.
iScience. 2025 Jan 3;28(2):111701. doi: 10.1016/j.isci.2024.111701. eCollection 2025 Feb 21.
Virus removal filtration during the manufacturing process plays an essential role in ensuring the virus safety of biologics. Following the revision of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q5A, the guidelines for the virus safety of biopharmaceuticals now state that an effective viral clearance process should achieve a viral reduction of 4 log or greater. Technological advances in the development of new manufacturing technologies for continuous production and the development of next-generation antibody drugs have increased the need for virus removal filters suited to a variety of applications. The newly available virus removal filter, Planova S20N, incorporates a newly developed regenerated cellulose hollow fiber membrane. In addition to stable filtration of a variety of antibody solutions, this filter demonstrates robust parvovirus removal under a variety of filtration operating conditions, including low flow rate filtration for continuous process.
在生物制品的生产过程中,病毒去除过滤对于确保生物制品的病毒安全性起着至关重要的作用。随着人用药品注册技术国际协调会议(ICH)Q5A的修订,生物制药病毒安全性指南现规定,有效的病毒清除过程应实现4 log或更大程度的病毒减少。连续生产新制造技术以及下一代抗体药物开发方面的技术进步,增加了对适用于各种应用的病毒去除过滤器的需求。新推出的病毒去除过滤器Planova S20N采用了新开发的再生纤维素中空纤维膜。除了能稳定过滤各种抗体溶液外,该过滤器在包括连续工艺的低流速过滤在内的各种过滤操作条件下,都表现出强大的细小病毒去除能力。